Study guide

3.3 Interstitial Lung Disease & Pleural Disorders

MRCPI in General Medicine Part I Written

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Strategy & Foundation

1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy

2 Chapter 2: Cardiology & Vascular Medicine

2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases

3 Chapter 3: Respiratory Medicine

3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea

4 Chapter 4: Gastroenterology & Hepatology

4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition

5 Chapter 5: Nephrology & Acid-Base Disorders

5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders

6 Chapter 6: Endocrinology & Diabetes

6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes

7 Chapter 7: Rheumatology & Clinical Immunology

7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology

8 Chapter 8: Haematology & Medical Oncology

8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies

9 Chapter 9: Neurology & Dermatology

9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease

10 Chapter 10: Acute Medicine, Critical Care & Geriatrics

10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care

11 Chapter 11: Clinical Pharmacology & Therapeutics

11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety

12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics

12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics

3.3 Interstitial Lung Disease & Pleural Disorders

Key Takeaways Explain This Topic AI

Idiopathic Pulmonary Fibrosis (IPF) is defined on High-Resolution CT (HRCT) by a Usual Interstitial Pneumonia (UIP) pattern featuring subpleural, basal-predominant reticular opacities, traction bronchiectasis, and honeycombing without atypical features.

Sarcoidosis presents with non-caseating granulomas; classic syndromes include Löfgren syndrome (erythema nodosum, bilateral hilar lymphadenopathy, migratory polyarthritis) and Heerfordt syndrome (uveoparotid fever, facial nerve palsy).

Light's criteria classify a pleural effusion as an exudate if any one of the following is met: pleural fluid/serum protein ratio >0.5, pleural fluid/serum LDH ratio >0.6, or pleural fluid LDH >2/3 the upper limit of normal serum LDH.

A pleural fluid pH <7.2 in the setting of a parapneumonic effusion indicates a complicated parapneumonic effusion or empyema, requiring urgent intercostal chest drain insertion regardless of fluid clarity or bacteriology.

In primary spontaneous pneumothorax, BTS guidelines mandate needle aspiration (16–18G cannula) if the patient is symptomatic or the rim of air is >2 cm at the level of the hilum; secondary spontaneous pneumothorax with air >2 cm requires immediate chest drain placement.

Last updated: July 2026

Interstitial Lung Diseases (ILD) & Idiopathic Pulmonary Fibrosis (IPF)

Interstitial Lung Diseases (ILDs) comprise a heterogeneous group of diffuse parenchymal lung disorders characterized by inflammation and/or fibrosis of the alveolar interstitium.

Classification Scheme

Idiopathic Interstitial Pneumonias : Idiopathic Pulmonary Fibrosis (IPF), Nonspecific Interstitial Pneumonia (NSIP), Cryptogenic Organizing Pneumonia (COP).

Granulomatous ILD : Sarcoidosis, Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis).

Connective Tissue Disease (CTD)-Associated ILD : Systemic sclerosis (scleroderma), Rheumatoid arthritis, Polymyositis/Dermatomyositis, Systemic lupus erythematosus.

Drug-Induced & Exposure-Related ILD : Amiodarone, Methotrexate, Nitrofurantoin, Bleomycin, asbestos, silica.

Idiopathic Pulmonary Fibrosis (IPF)

IPF is a progressive, fatal fibrotic lung disease occurring primarily in individuals >60 years of age.

Clinical Presentation : Progressive exertional dyspnoea, chronic dry cough, bilateral digital clubbing (50%), and fine end-inspiratory "velcro-like" crackles at lung bases.

Pulmonary Function Tests (PFTs) : Classic restrictive defect showing reduced Forced Vital Capacity ( FVC <80% predicted ), normal or elevated FEV1/FVC ratio (>0.70/0.80), and markedly reduced Transfer Factor for Carbon Monoxide ( TLCO/DLCO <40–60% predicted ).

High-Resolution CT (HRCT) Gold Standard : Shows the Usual Interstitial Pneumonia (UIP) pattern:

  • Bilateral subpleural and basal-predominant reticular opacities,
  • Traction bronchiectasis and bronchiolectasis,
  • Honeycombing (stacked subpleural cystic air spaces with thick walls),

Absence of upper-lobe dominance, prominent ground-glass opacities, or mosaic attenuation.

Disease-Modifying Pharmacotherapy :

Pirfenidone : Orally administered antifibrotic agent that inhibits TGF-β production and collagen synthesis.

Nintedanib : Intracellular triple tyrosine kinase inhibitor targeting PDGF, FGF, and VEGF receptors. Clinical Evidence : Both agents slow the rate of FVC decline in mild-to-moderate IPF (FVC 50–80%).

Contrarian Exam Warning : Long-term systemic corticosteroids are CONTRAINDICATED in IPF! The randomized controlled PANTHER-IPF trial demonstrated that triple therapy with prednisolone, azathioprine, and N-acetylcysteine caused increased mortality and hospitalisations compared to placebo. Corticosteroids are reserved strictly for acute IPF exacerbations.

Sarcoidosis & Granulomatous Diseases

Sarcoidosis is a multisystem granulomatous disorder characterized by non-caseating epithelioid granulomas.

Classic Clinical Syndromes

Löfgren Syndrome : Acute, self-limiting presentation characterized by the triad of:

  • Erythema Nodosum (painful, erythematous subcutaneous nodules on anterior shins),
  • Bilateral Hilar Lymphadenopathy (BHL) on chest radiograph, and

Migratory Polyarthritis (predominantly involving ankle joints). Prognosis : Excellent spontaneous remission rate (>85%); managed symptomatically with NSAIDs.

Heerfordt Syndrome (Uveoparotid Fever) : Rare acute manifestation featuring uveitis (anterior or posterior), parotid gland enlargement, facial nerve palsy (CN VII), and low-grade fever.

Diagnostic & Laboratory Findings

Serum Angiotensin-Converting Enzyme (ACE) : Elevated in ~60% of active cases (produced by epithelioid cells within granulomas).

Calcium Metabolism Anomalies : Hypercalcaemia and hypercalciuria occur in 10–20% of patients due to extra-renal 1-alpha-hydroxylase expression by activated granuloma macrophages, converting 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D3.

Bronchoalveolar Lavage (BAL) : Lymphocytic alveolitis with an elevated CD4/CD8 ratio (>3.5) .

Radiographic Staging :

Stage 0: Normal chest radiograph.

Stage 1: Bilateral Hilar Lymphadenopathy (BHL) alone.

Stage 2: BHL plus parenchymal lung infiltrates.

Stage 3: Parenchymal infiltrates without BHL.

Stage 4: End-stage pulmonary fibrosis (honeycombing, volume loss).

Corticosteroid Indications

Systemic oral corticosteroids (Prednisolone 20–40 mg daily) are indicated for organ-threatening or symptomatic disease :

  • Cardiac sarcoidosis (conduction block, ventricular arrhythmias),
  • Neurosarcoidosis (cranial neuropathies, mass lesions),
  • Ocular sarcoidosis refractory to topical drops,
  • Severe hypercalcaemia,

Progressive pulmonary function loss (falling FVC/TLCO).

Pleural Effusion Pathophysiology & Light's Criteria

Pleural effusions represent excess fluid accumulation in the pleural space, classified as either transudates or exudates.

Pathophysiological Distinction

Transudates (Protein <30 g/L) : Caused by systemic factors altering hydrostatic or oncotic pressures (e.g., Left ventricular failure, Liver cirrhosis, Nephrotic syndrome, Hypoalbuminaemia).

Exudates (Protein >30 g/L) : Caused by local disease altering pleural microvascular permeability (e.g., Malignancy, Pneumonia, Pulmonary embolism, Tuberculosis, Rheumatoid arthritis).

Light's Criteria

When pleural fluid protein concentration is borderline ( 25–35 g/L ), Light's Criteria must be evaluated. Fluid is defined as an EXUDATE if ANY ONE of the following three criteria is satisfied:

  • Pleural Fluid Protein / Serum Protein Ratio > 0.5
  • Pleural Fluid LDH / Serum LDH Ratio > 0.6
  • Pleural Fluid LDH > 2/3 of the Upper Limit of Normal Serum LDH

Diagnostic Test Finding Diagnostic Implication

Pleural Fluid Glucose <3.3 mmol/L Empyema, Rheumatoid arthritis (often <1.0 mmol/L), Tuberculosis, Malignancy, Lupus

  • Pleural Fluid pH <7.2 Complicated parapneumonic effusion, Empyema, Rheumatoid arthritis, Esophageal rupture
  • Pleural Fluid Amylase >Upper limit of normal serum amylase Acute pancreatitis, Esophageal rupture

Pleural Fluid Haematocrit >50% of peripheral blood haematocrit True Haemothorax (requires chest drain placement)

  • Empyema & Pneumothorax BTS Guidelines
  • Complicated Parapneumonic Effusion & Empyema

Parapneumonic effusions develop adjacent to bacterial pneumonia. Bacterial invasion of the pleural space triggers fibrin deposition and loculation.

BTS Criteria for Intercostal Chest Drain Insertion :

  • Frank pus or turbid/foul-smelling fluid aspirated on thoracocentesis,
  • Organisms identified on Gram stain or pleural fluid culture,

Pleural fluid pH <7.2 in a patient with parapneumonic effusion.

Management Protocol : Immediate small-bore intercostal chest drain placement (12–14F), targeted IV antibiotics, and consideration of intrapleural tissue plasminogen activator (tPA) plus recombinant human DNase for loculated effusions.

  • Pneumothorax BTS Management Algorithm Primary Spontaneous Pneumothorax (PSP)
  • │

Is Rim of Air >2 cm at Hilum OR Breathless?

  • ┌──┴──┐
  • Yes No
  • │ │
  • Needle Aspiration (16-18G) Discharge & Outpatient
  • │ Review in 2-4 Weeks
  • Successful? (<2 cm)
  • ┌─┴─┐
  • Yes No
  • │ │
  • Discharge Intercostal Chest Drain (12-14F)

Primary Spontaneous Pneumothorax (PSP) : No underlying lung disease.

Rim <2 cm and asymptomatic : Discharge with safety netting; outpatient review in 2–4 weeks.

Rim ≥2 cm OR breathless : Needle aspiration (16–18G cannula in 2nd intercostal space mid-clavicular line). If aspiration reduces rim to <2 cm, discharge. If aspiration fails (rim remains ≥2 cm), insert a small-bore chest drain (12–14F).

Secondary Spontaneous Pneumothorax (SSP) : Occurs in patients with underlying lung disease (COPD, CF, ILD).

Rim >2 cm OR breathless : Insert intercostal chest drain immediately and admit.

Rim 1–2 cm : Perform needle aspiration; if successful (<1 cm), admit for 24 hours observation. If aspiration fails, insert chest drain.

Rim <1 cm : Admit for 24 hours observation and high-flow oxygen.

Tension Pneumothorax : Emergency clinical diagnosis (hypotension, tracheal deviation away from affected side, distended neck veins, hyper-resonance, absent breath sounds). Perform immediate emergency decompression with a large-bore cannula (14G) inserted into the 2nd intercostal space mid-clavicular line , followed by formal intercostal chest drain placement.